KEMPHARM INC

KMPH NASDAQ

CryptoFundManager

Investors in KemPharm, Inc. KMPH need to pay close attention to the stock based on moves in the options market lately. That is because the Apr 16, 2021 $35.00 Call had some of the highest implied volatility of all equity options. (zacks.com) What are the fundamentals and TA that can make skyrocket KMPH KemPharm more that 300%??? 1. They have no debt! Listed on...

Michael_6ivenchy

Bullish

follow_the_money

Recently approved ADHD med. CEO Travis Mickle helped develop current market leader Vyvance (also ADHD med) and now with a new and improved iteration (Aztrazyris) . Also worth to note Mickle sold his previous company (new river) to shire then shire was bought out by Takeda for bucku bucks and now Mickle is working with ex-shire CEO to bring this baby to market!...

00:00

CobraTrader13

My watchlist for this week: FDA Hype $ACAD $AVEO Swings $RKDA $APRE $ATOS $SBBP $KMPH Like and follow for more :) Happy Trading!

GodOfThund3r

Floor 8.9-9.0 and breaking down trend

BigDipNick

It seems to me that all of the shorter term EMA's are charting into a descending, converging triangle. The tipping point target is right around the current closing price of $10.62. I believe tomorrow, 3/23 will be a very big day in deciding the short term value for KMPH. It appears to be a great long term hold for people that have the time. As far as day trading...

jpactor

I'm very bullish on this and long in the position. The Reddit WSB are starting to get behind it and I'm seeing more buying on the tape in large volume than selling. Shorts are in a bad place. Could see 20.00, 60.00, 90.00, or 120.00 conservatively due to very small float compared to the floats of GME or AMC. Full disclosure I'm am long this stock and have been...

jpactor

I brought up this idea on WSBN discord about a week ago and I think it's starting to line up. Just as GME was a heavily shorted stock so has been KMPH with a 71% short interest as of yesterday. The company has a major catalyst with an FDA approved ADHD drug that is better than anything else out there on the market. Having ADHD I have been very interested in this...

CryptoFundManager

Short Float 71.13% (Source: Finviz) Insider Own 7.12% A significant ownership by insiders increases the chance that the company is run in the interest of all shareholders, but it is also heavily shorted because not to many institutions hold the shares. Institutional Own 2.80% 1. They have no debt! which is fantastic! 2. They received gross proceeds of...

CryptoFundManager

Target 1: $29 Target 2: $45 Target 3: $80 If you are interested to test some amazing BUY and SELL INDICATORS which give the signal at the beginning of the candle, not at the end of it, just leave me a message.

CryptoFundManager

I know that the Pre-Market shows a -13.73% selloff, but i think it`s a fake wall made to determine you to sell your shares. My target is 29usd at the moment. KemPharm, Inc. KMPH announced yesterday that the FDA has approved its new drug application (“NDA”) for Azstarys a prodrug of methylphenidate for the treatment of attention deficit hyperactivity disorder...

AlenCiken

KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD Corium, Inc. will lead the commercialization of AZSTARYS per the definitive collaboration and license agreement. Corium expects to make AZSTARYS commercially available in the U.S. as early as the second...

RJLeo82

See chart for 618% bounce, stop below gap for more risk

trilliondollar

FDA approval with potential short squeeze. Without these catalyst the market cap still suggests that it is undervalued with the new addressable market of KP415/AZSTARYS

jahoozy

This week KMPH is awaiting FDA approval, expect catalyst to come to drive price up Buy at dips to expect pop Be mindful of bearish momentum as of recently Something like that

BDRTrigger33

$KMPH has very weak support and could retrace much lower regions in near completion of a head and shoulders formation. All signs are grossly bearish, including many large-scale sell orders having been placed in the last five days. The bigger investors have pulled the rug-- Target new entries much lower on this position if possible. Best, BDR

Daulet_Kali

KemPharm, Inc., a specialized pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its candidate product includes KP415 and KP484 for the treatment of attention deficit disorder. (ADHD) For reference: ADHD has a huge market and no cures have been invented in over 10 years. If the KP415 is FDA approved (March 2), it will...

aeyildir

KMPH cloud entry rejected at the bottom of cloud.